Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus QNASL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus QNASL.
CORTIFOAM vs QNASL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins and leukotrienes, and reducing nasal inflammation.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
1 to 2 sprays (80 mcg/spray) per nostril once daily; maximum 2 sprays/nostril/day.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
The terminal elimination half-life is approximately 8-10 hours in healthy adults, supporting twice-daily administration for systemic effects; however, intranasal administration results in minimal systemic absorption, and local half-life in nasal tissues is not well characterized.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
The majority of a dose (approximately 40-50%) is excreted in feces as unchanged drug and metabolites, with about 10-15% excreted in urine as metabolites. Biliary excretion is the primary route of elimination.
Category C
Category C
Corticosteroid
Corticosteroid